OKUR · Categories · Form 4

OKUR - SEC Form 4 insider transactions

OnKure Therapeutics Inc. (OKUR) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for OKUR

• 61d
  SEC Form 4 filed by Saccomano Nicholas A

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 61d
  SEC Form 4 filed by Leverone Jason A.

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 61d
  SEC Form 4 filed by Hartley Dylan

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 61d
  SEC Form 4 filed by Agresta Samuel

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 63d
  SEC Form 4 filed by Ratcliffe Liam

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 71d
  SEC Form 4 filed by Saccomano Nicholas A

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 71d
  SEC Form 4 filed by Leverone Jason A.

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 152d
  Director Mathers Edward T was granted 3,911 shares, increasing direct ownership by 34% to 15,310 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 152d
  Director Manke Isaac was granted 5,258 shares, increasing direct ownership by 34% to 20,583 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 162d
  President and CEO Saccomano Nicholas A sold $258 worth of shares (87 units at $2.97), decreasing direct ownership by 1% to 7,419 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 162d
  Chief Financial Officer Leverone Jason A. sold $896 worth of shares (302 units at $2.97), decreasing direct ownership by 2% to 16,301 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 244d
  Director Mathers Edward T was granted 4,125 shares, increasing direct ownership by 57% to 11,399 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 244d
  Director Manke Isaac was granted 5,545 shares, increasing direct ownership by 57% to 15,325 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 252d
  President and CEO Saccomano Nicholas A sold $231 worth of shares (88 units at $2.62), decreasing direct ownership by 2% to 3,506 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 252d
  Chief Financial Officer Leverone Jason A. sold $795 worth of shares (303 units at $2.62), decreasing direct ownership by 2% to 12,603 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 336d
  Director Mathers Edward T was granted 4,694 shares, increasing direct ownership by 182% to 7,274 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 336d
  Director Manke Isaac was granted 6,311 shares, increasing direct ownership by 182% to 9,780 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 343d
  President and CEO Saccomano Nicholas A sold $210 worth of shares (88 units at $2.38), decreasing direct ownership by 2% to 3,594 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 343d
  Chief Financial Officer Leverone Jason A. sold $722 worth of shares (303 units at $2.38), decreasing direct ownership by 2% to 12,906 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Mathers Edward T

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Phillips Andrew John

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Manke Isaac

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Jansen Valerie Malyvanh

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Grey Michael G

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 369d
  SEC Form 4 filed by Director Carruthers R Michael

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 380d
  Former 10% Owner Cormorant Asset Management, Lp sold $3,363,023 worth of shares (1,813,439 units at $1.85) (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 385d
  Large owner Cormorant Asset Management, Lp sold $48,236 worth of shares (24,300 units at $1.99) (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 421d
  President and CEO Saccomano Nicholas A sold $2,570 worth of shares (874 units at $2.94), decreasing direct ownership by 19% to 3,682 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 421d
  Chief Financial Officer Leverone Jason A. sold $9,178 worth of shares (3,122 units at $2.94), decreasing direct ownership by 19% to 13,209 units (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 427d
  Director Mathers Edward T was granted 2,580 shares (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 427d
  Director Manke Isaac was granted 3,469 shares (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 490d
  SEC Form 4 filed by President and CEO Saccomano Nicholas A

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 490d
  SEC Form 4 filed by Chief Financial Officer Leverone Jason A.

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 490d
  SEC Form 4 filed by Chief Scientific Officer Hartley Dylan

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 490d
  SEC Form 4 filed by Chief Medical Officer Agresta Samuel

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
• 602d
  Former 10% owner of RPHM Leonard Braden Michael acquired 447,815 shares (SEC Form 4)

  4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

Other OKUR categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends